Your Health, We Care
Cabozantinib is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
Cabozantinib, in combination with nivolumab, is indicated for the first-line treatment of patients with advanced RCC.
Cabozantinib is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Cabozantinib is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
from FDA，2023.09
This article is the package insert for Cabozantinib (LuciCaboz) tablets. Do not ···【more】
Release date：2026-10-23Recommended：67
Cabozantinib (LuciCaboz), tablets 20mg. Date of first US approval: 2012.Indicati···【more】
Release date：2026-10-23Recommended：67
Cabozantinib (Cabometyx) was first approved by the FDA in 2012. It is a non‑spec···【more】
Release date：2026-03-20Recommended：270
On March 26, 2025, Exelixis, Inc. announced that the U.S. Food and Drug Administ···【more】
Release date：2026-03-20Recommended：309
Cabozantinib is a non-chemotherapy prescription medication classified as a tyros···【more】
Release date：2026-02-05Recommended：379
Cabozantinib has been approved for the treatment of various cancers.【more】
Release date：2026-01-06Recommended：275
Cabozantinib is a multi-kinase inhibitor that has demonstrated significant effic···【more】
Release date：2025-02-17Recommended：475
Cabozantinib is a multi-targeted tyrosine kinase inhibitor with a wide range of ···【more】
Release date：2025-02-17Recommended：471
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that plays an importa···【more】
Release date：2025-02-13Recommended：486
Cabotinib is a multi-targeted tyrosine kinase inhibitor that has shown broad pot···【more】
Release date：2025-02-13Recommended：504
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
